ORIC® PHARMACEUTICALS ANNOUNCES AGREEMENT WITH CANCER RESEARCH UK TO ADVANCE A POTENTIAL FIRST-IN-CLASS CIP2A-TARGETED THERAPY INTO CLINICAL DEVELOPMENT

Reuters · 2d ago

Please log in to view news